Free Trial

Promising Pharmaceutical Stocks To Consider - October 18th

Eli Lilly and Company logo with Medical background

Key Points

  • Eli Lilly, Gilead Sciences, and AbbVie are the top pharmaceutical stocks to watch according to MarketBeat, based on recent trading volume and market activity.
  • Eli Lilly specializes in diabetes and obesity treatments, while Gilead Sciences focuses on medicines for HIV/AIDS and COVID-19, illustrating diverse product portfolios in the pharmaceutical sector.
  • AbbVie is notable for its extensive range of treatments for autoimmune diseases and cancers, showcasing the potential growth within the biopharmaceutical market.
  • Five stocks to consider instead of Eli Lilly and Company.

Eli Lilly and Company, Gilead Sciences, and AbbVie are the three Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies whose primary business is researching, developing, manufacturing, and marketing prescription drugs, vaccines, and related biologic therapies. For investors, these stocks are influenced by factors such as drug trial results, regulatory approvals, patent protection, pricing and reimbursement policies, and long development timelines, which can create both high growth potential and elevated regulatory and pipeline risk. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Read Our Latest Research Report on GILD

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Read Our Latest Research Report on ABBV

Featured Stories

Should You Invest $1,000 in Eli Lilly and Company Right Now?

Before you consider Eli Lilly and Company, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.

While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Palantir’s New Deal: Is it an Earnings Signal Investors Can’t Ignore?
From $1 to $15: The Rare Earth Stocks Powering Massive Gains
3 Undervalued Energy Stocks Under $20 with Big Potential

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines